With the continuing COVID-19 pandemic, identifying medications that improve COVID-19 outcomes is crucial. Studies suggest that use of metformin, an oral antihyperglycemic, is associated with reduced COVID-19 severity in individuals with diabetes compared to other antihyperglycemic medications. Some patients without diabetes, including those with polycystic ovary syndrome (PCOS) and prediabetes, are prescribed metformin for off-label use, which provides an opportunity to further investigate the effect of metformin on COVID-19.
Metformin is Associated with Reduced COVID-19 Severity in Patients with Prediabetes / L.E. Chan, E. Casiraghi, B. Laraway, B. Coleman, H. Blau, A. Zaman, N. Harris, K. Wilkins, M. Gargano, G. Valentini, D. Sahner, M. Haendel, P.N. Robinson, C. Bramante, J. Reese. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - 194:(2022 Dec), pp. 110157.1-110157.11. [10.1016/j.diabres.2022.110157]
Metformin is Associated with Reduced COVID-19 Severity in Patients with Prediabetes
E. CasiraghiSecondo
;G. Valentini;
2022
Abstract
With the continuing COVID-19 pandemic, identifying medications that improve COVID-19 outcomes is crucial. Studies suggest that use of metformin, an oral antihyperglycemic, is associated with reduced COVID-19 severity in individuals with diabetes compared to other antihyperglycemic medications. Some patients without diabetes, including those with polycystic ovary syndrome (PCOS) and prediabetes, are prescribed metformin for off-label use, which provides an opportunity to further investigate the effect of metformin on COVID-19.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Diabetes_Care.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.09 MB
Formato
Adobe PDF
|
1.09 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
